

available at www.sciencedirect.com



www.elsevier.com/locate/brainres

# BRAIN RESEARCH

## Research Report

# Similar in vitro pharmacology of human cannabinoid CB<sub>1</sub> receptor variants expressed in CHO cells

Jing Chen Xiao<sup>a</sup>, James P. Jewell<sup>b</sup>, Linus S. Lin<sup>b</sup>, William K. Hagmann<sup>b</sup>, Tung M. Fong<sup>a</sup>, Chun-Pyn Shen<sup>a,\*</sup>

<sup>a</sup>Department of Metabolic Disorders Merck Research Laboratories, Rahway, NJ 07065, USA <sup>b</sup>Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA

#### ARTICLEINFO

### Article history: Accepted 5 August 2008 Available online 18 August 2008

#### Keywords:

Human cannabinoid CB<sub>1</sub> receptor Human cannabinoid CB<sub>1a</sub> receptor Human cannabinoid CB<sub>1b</sub> receptor Endocannabinoid CB<sub>1</sub> receptor inverse agonist

#### ABSTRACT

Through alternative splicing, the human cannabinoid  $CB_1$  receptor gene encodes three variants of protein products ( $hCB_1$ ,  $hCB_{1a}$ , and  $hCB_{1b}$ ) that differ in amino acid sequence at the N terminus of the receptors. By semi-quantitative PCR from human adult and fetal brain mRNA, we demonstrated that the transcript encoding  $hCB_1$  is the major transcript, and estimated that those of  $hCB_{1a}$  and  $hCB_{1b}$  represent fewer than 5% of the total human cannabinoid  $CB_1$  receptor transcripts. We characterized the three variants stably expressed in CHO cells. In the contrary to the study by Ryberg et al. (FEBS Lett 579[1], 259-64), we did not find substantial difference among the three variants according to the binding affinity, functional potency, and efficacy of meth-anandamide, 2-arachidonoyl glycerol, virodhamine, Noladin ether, docosatetraenylethanolamide, CP55940, AM251, and compound 35e (an acyclic class human  $CB_1$  receptor inverse agonist similar to MK-0364). The functional significance of different human cannabinoid  $CB_1$  receptor variants remains to be clarified.

© 2008 Elsevier B.V. All rights reserved.

#### 1. Introduction

The cannabinoid CB<sub>1</sub> receptor gene is widely and highly expressed in the central nervous system (Matsuda et al., 1990; Herkenham et al., 1990; Tsou et al., 1998). Low level expression of the receptor has also been identified in a variety of peripheral organs (Pertwee, 2001; Croci et al., 1998; Di Marzo et al., 2001, Szabo et al., 2001; Wagner et al., 2001; Wang et al., 2004). Based on the results from studies of the cannabinoid CB<sub>1</sub> receptor gene knock-out mice, CB<sub>1</sub> receptor plays a role in regulating body temperature, nociceptive sensation, and feeding behavior (Zimmer et al., 1999; Ledent et al., 1999; Di Marzo et al., 2001).

The cannabinoid CB<sub>1</sub> receptor is a member of the sevenmembrane-spanning receptor family and interacts with the heterotrimeric G proteins to regulate ion channel activities, cAMP production, and to activate the mitogen-activated protein kinase cascade (Matsuda et al., 1990; Gerard et al., 1991; Mackie et al., 1995; Bouaboula et al., 1995). Multiple endocannabinoid and small molecule ligands can interact with cannabinoid CB<sub>1</sub> receptor as agonist or inverse agonist. Anandamide and 2-arachidonoyl glycerol are endogenous cannabinoid ligands, which are fatty acid derivatives (Devane et al., 1992; Mechoulam et al., 1995). Noladin ether, virodhamine, and docosatetraenylethanolamide, which are also fatty acid derivatives, have been reported as ligands for cannabinoid CB<sub>1</sub> receptor (Hanus et al., 1993, 2001; Porter et al., 2002. In additional to the classical cannabinoid (CP55940) and the

<sup>\*</sup> Corresponding author. Fax: +1 732 594 3337. E-mail address: chunpyn\_shen@merck.com (C.-P. Shen).

aminoalkylindole (WIN55212-2) also are cannabinoid  $CB_1$  receptor agonists (Huffman et al., 1996; Melvin et al., 1995; D'Ambra et al., 1992; Luk et al., 2004). SR141716A, and the closely related analog AM251, are cannabinoid  $CB_1$  receptor inverse agonists (Rinaldi-Carmona et al., 1994; Bouaboula et al., 1997). MK-0364 and compound 35e were newly identified cannabinoid  $CB_1$  receptor inverse agonists, which belong to the acyclic class of inverse agonist (Lin et al., 2006).

Through alternative splicing the human cannabinoid  $CB_1$  receptor gene encodes three variants of protein products (hCB<sub>1</sub>, hCB<sub>1a</sub>, and hCB<sub>1b</sub>), differing in amino acid sequence at the N terminus of the receptors (Shire et al., 1995; Rinaldi-Carmona et al., 1996; Ryberg et al., 2005). It has been reported that Noladin ether and anandamide exhibited little affinity or potency for hCB<sub>1a</sub> and hCB<sub>1b</sub> variants and that 2-arachidonoyl glycerol functioned as an inverse agonist at hCB<sub>1a</sub> and hCB<sub>1b</sub> variants, when the variants were transiently




Fig. 1 – Detecting the human cannabinoid  $CB_1$  receptor variants,  $CB_1$ ,  $CB_{1a}$  and  $CB_{1b}$ , with variant-specific primer pairs by PCR from adult and fetal human brain cDNA libraries. (A) Schematic representation of the primers used to generate  $CB_1$ ,  $CB_{1a}$  and  $CB_{1b}$ , related PCR products. " $\blacktriangleright$ ": common forward primer; " $\hookleftarrow$ ": common reverse primer; " $\smile$ ": variant-specific forward primers, which cross the RNA splicing site. "ATG": translation initiation for  $CB_1$ , and  $CB_{1b}$ , "ATG": translation initiation for  $CB_{1a}$ ; (B) Variant-specific primer pairs only generating PCR products from the specific variant cDNA template (C) Relative abundance of  $CB_{1a}$ ,  $CB_{1b}$  and  $CB_{1b}$  variant transcripts in human adult or fetal brain cDNA libraries. ">": marked the slower migrating band to be  $CB_1$  product, confirmed by cloning and sequencing.

## Download English Version:

# https://daneshyari.com/en/article/4329199

Download Persian Version:

https://daneshyari.com/article/4329199

Daneshyari.com